| Characteristics . | All (N = 56) . | Atezolizumab + EP (N = 14) . | EP alone (N = 42) . | P-value . |
|---|---|---|---|---|
| Age | ||||
| Median ± SD | 62.2 ± 13.9 | 58.8 ± 12.3 | 64.4 ± 14.8 | .343 |
| Age ≥ 65 years, No. (%) | 24 (42.9) | 4 (28.5) | 20 (47.6) | .35 |
| Male sex, No. (%) | 36 (64.3) | 9 (64.3) | 27 (64.3) | 1.0 |
| ECOG performance status | .373 | |||
| 0 | 38 (67.9) | 10 (71.4) | 28 (66.7) | |
| 1 | 11 (19.6) | 4 (28.6) | 7 (16.7) | |
| 2 | 4 (7.14) | 0 (0) | 4 (9.5) | |
| Not available | 3 (5.4) | 0 (0) | 3 (7.1) | |
| Primary site, No. (%) | .14 | |||
| Pancreas | 11 (19.6) | 6 (42.9) | 5 (11.9) | |
| Biliary tract | 8 (14.3) | 3 (21.4) | 5 (11.9) | |
| Colon | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Stomach | 6 (10.7) | 1 (7.1) | 5 (11.9) | |
| Esophagus | 3 (5.4) | 0 (0) | 3 (7.1) | |
| genitourinary tract | 7 (12.5) | 0 (0) | 7 (16.7) | |
| Unknown (Not lung) | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Other (≤2 cases) | 5 (8.9) | 0 (0) | 5 (11.9) | |
| Metastasis site | .78 | |||
| Peritoneum | 19 (33.9) | 5 (35.7) | 14 (25) | |
| Bone | 9 (16.1) | 2 (14.3) | 7 (12.5) | |
| Liver | 36 (64.3) | 13 (92.8) | 23 (41.1) | |
| Brain | 1 (1.8) | 0 (0) | 1 (1.8) | |
| Lung | 13 (23.2) | 3 (21.3) | 10 (17.6) | |
| Ki-67 index | ||||
| Mean ± SD (range) | 80 ± 12.2 | 79.6 ± 17.1 | 76.7 ± 18.5 | .4 |
| >55% | 37 (66.1) | 11 (78.5) | 26 (61.9) | .32 |
| NA | 11 (19.6) | 1 (7.1) | 10 (23.8) | |
| Cisplatin/Carboplatin (N) | 43/13 | 11/3 | 32/10 | 1.0 |
| Cumulative dose intensitya | ||||
| Platinum, mean (range) | 0.90 (0.48-1.05) | 0.91 (0.48-1.05) | 0.90 (0.48-1.03) | .94 |
| Etoposide, mean (range) | 0.75 (0.36-1.01) | 0.71 (0.36-0.9) | 0.76 (0.38-1.01) | .23 |
| Characteristics . | All (N = 56) . | Atezolizumab + EP (N = 14) . | EP alone (N = 42) . | P-value . |
|---|---|---|---|---|
| Age | ||||
| Median ± SD | 62.2 ± 13.9 | 58.8 ± 12.3 | 64.4 ± 14.8 | .343 |
| Age ≥ 65 years, No. (%) | 24 (42.9) | 4 (28.5) | 20 (47.6) | .35 |
| Male sex, No. (%) | 36 (64.3) | 9 (64.3) | 27 (64.3) | 1.0 |
| ECOG performance status | .373 | |||
| 0 | 38 (67.9) | 10 (71.4) | 28 (66.7) | |
| 1 | 11 (19.6) | 4 (28.6) | 7 (16.7) | |
| 2 | 4 (7.14) | 0 (0) | 4 (9.5) | |
| Not available | 3 (5.4) | 0 (0) | 3 (7.1) | |
| Primary site, No. (%) | .14 | |||
| Pancreas | 11 (19.6) | 6 (42.9) | 5 (11.9) | |
| Biliary tract | 8 (14.3) | 3 (21.4) | 5 (11.9) | |
| Colon | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Stomach | 6 (10.7) | 1 (7.1) | 5 (11.9) | |
| Esophagus | 3 (5.4) | 0 (0) | 3 (7.1) | |
| genitourinary tract | 7 (12.5) | 0 (0) | 7 (16.7) | |
| Unknown (Not lung) | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Other (≤2 cases) | 5 (8.9) | 0 (0) | 5 (11.9) | |
| Metastasis site | .78 | |||
| Peritoneum | 19 (33.9) | 5 (35.7) | 14 (25) | |
| Bone | 9 (16.1) | 2 (14.3) | 7 (12.5) | |
| Liver | 36 (64.3) | 13 (92.8) | 23 (41.1) | |
| Brain | 1 (1.8) | 0 (0) | 1 (1.8) | |
| Lung | 13 (23.2) | 3 (21.3) | 10 (17.6) | |
| Ki-67 index | ||||
| Mean ± SD (range) | 80 ± 12.2 | 79.6 ± 17.1 | 76.7 ± 18.5 | .4 |
| >55% | 37 (66.1) | 11 (78.5) | 26 (61.9) | .32 |
| NA | 11 (19.6) | 1 (7.1) | 10 (23.8) | |
| Cisplatin/Carboplatin (N) | 43/13 | 11/3 | 32/10 | 1.0 |
| Cumulative dose intensitya | ||||
| Platinum, mean (range) | 0.90 (0.48-1.05) | 0.91 (0.48-1.05) | 0.90 (0.48-1.03) | .94 |
| Etoposide, mean (range) | 0.75 (0.36-1.01) | 0.71 (0.36-0.9) | 0.76 (0.38-1.01) | .23 |
Abbreviations: EP: Etoposide + platinum, N = number.
aCumulative dose intensity: calculated as the cumulative actual dose divided by (standard dose × total cycles administered). The standard doses are cisplatin 75 mg/m² or carboplatin 5 AUC in day1 and etoposide 100 mg/m² on day 1 to day 3.
| Characteristics . | All (N = 56) . | Atezolizumab + EP (N = 14) . | EP alone (N = 42) . | P-value . |
|---|---|---|---|---|
| Age | ||||
| Median ± SD | 62.2 ± 13.9 | 58.8 ± 12.3 | 64.4 ± 14.8 | .343 |
| Age ≥ 65 years, No. (%) | 24 (42.9) | 4 (28.5) | 20 (47.6) | .35 |
| Male sex, No. (%) | 36 (64.3) | 9 (64.3) | 27 (64.3) | 1.0 |
| ECOG performance status | .373 | |||
| 0 | 38 (67.9) | 10 (71.4) | 28 (66.7) | |
| 1 | 11 (19.6) | 4 (28.6) | 7 (16.7) | |
| 2 | 4 (7.14) | 0 (0) | 4 (9.5) | |
| Not available | 3 (5.4) | 0 (0) | 3 (7.1) | |
| Primary site, No. (%) | .14 | |||
| Pancreas | 11 (19.6) | 6 (42.9) | 5 (11.9) | |
| Biliary tract | 8 (14.3) | 3 (21.4) | 5 (11.9) | |
| Colon | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Stomach | 6 (10.7) | 1 (7.1) | 5 (11.9) | |
| Esophagus | 3 (5.4) | 0 (0) | 3 (7.1) | |
| genitourinary tract | 7 (12.5) | 0 (0) | 7 (16.7) | |
| Unknown (Not lung) | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Other (≤2 cases) | 5 (8.9) | 0 (0) | 5 (11.9) | |
| Metastasis site | .78 | |||
| Peritoneum | 19 (33.9) | 5 (35.7) | 14 (25) | |
| Bone | 9 (16.1) | 2 (14.3) | 7 (12.5) | |
| Liver | 36 (64.3) | 13 (92.8) | 23 (41.1) | |
| Brain | 1 (1.8) | 0 (0) | 1 (1.8) | |
| Lung | 13 (23.2) | 3 (21.3) | 10 (17.6) | |
| Ki-67 index | ||||
| Mean ± SD (range) | 80 ± 12.2 | 79.6 ± 17.1 | 76.7 ± 18.5 | .4 |
| >55% | 37 (66.1) | 11 (78.5) | 26 (61.9) | .32 |
| NA | 11 (19.6) | 1 (7.1) | 10 (23.8) | |
| Cisplatin/Carboplatin (N) | 43/13 | 11/3 | 32/10 | 1.0 |
| Cumulative dose intensitya | ||||
| Platinum, mean (range) | 0.90 (0.48-1.05) | 0.91 (0.48-1.05) | 0.90 (0.48-1.03) | .94 |
| Etoposide, mean (range) | 0.75 (0.36-1.01) | 0.71 (0.36-0.9) | 0.76 (0.38-1.01) | .23 |
| Characteristics . | All (N = 56) . | Atezolizumab + EP (N = 14) . | EP alone (N = 42) . | P-value . |
|---|---|---|---|---|
| Age | ||||
| Median ± SD | 62.2 ± 13.9 | 58.8 ± 12.3 | 64.4 ± 14.8 | .343 |
| Age ≥ 65 years, No. (%) | 24 (42.9) | 4 (28.5) | 20 (47.6) | .35 |
| Male sex, No. (%) | 36 (64.3) | 9 (64.3) | 27 (64.3) | 1.0 |
| ECOG performance status | .373 | |||
| 0 | 38 (67.9) | 10 (71.4) | 28 (66.7) | |
| 1 | 11 (19.6) | 4 (28.6) | 7 (16.7) | |
| 2 | 4 (7.14) | 0 (0) | 4 (9.5) | |
| Not available | 3 (5.4) | 0 (0) | 3 (7.1) | |
| Primary site, No. (%) | .14 | |||
| Pancreas | 11 (19.6) | 6 (42.9) | 5 (11.9) | |
| Biliary tract | 8 (14.3) | 3 (21.4) | 5 (11.9) | |
| Colon | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Stomach | 6 (10.7) | 1 (7.1) | 5 (11.9) | |
| Esophagus | 3 (5.4) | 0 (0) | 3 (7.1) | |
| genitourinary tract | 7 (12.5) | 0 (0) | 7 (16.7) | |
| Unknown (Not lung) | 8 (14.3) | 2 (14.3) | 6 (14.3) | |
| Other (≤2 cases) | 5 (8.9) | 0 (0) | 5 (11.9) | |
| Metastasis site | .78 | |||
| Peritoneum | 19 (33.9) | 5 (35.7) | 14 (25) | |
| Bone | 9 (16.1) | 2 (14.3) | 7 (12.5) | |
| Liver | 36 (64.3) | 13 (92.8) | 23 (41.1) | |
| Brain | 1 (1.8) | 0 (0) | 1 (1.8) | |
| Lung | 13 (23.2) | 3 (21.3) | 10 (17.6) | |
| Ki-67 index | ||||
| Mean ± SD (range) | 80 ± 12.2 | 79.6 ± 17.1 | 76.7 ± 18.5 | .4 |
| >55% | 37 (66.1) | 11 (78.5) | 26 (61.9) | .32 |
| NA | 11 (19.6) | 1 (7.1) | 10 (23.8) | |
| Cisplatin/Carboplatin (N) | 43/13 | 11/3 | 32/10 | 1.0 |
| Cumulative dose intensitya | ||||
| Platinum, mean (range) | 0.90 (0.48-1.05) | 0.91 (0.48-1.05) | 0.90 (0.48-1.03) | .94 |
| Etoposide, mean (range) | 0.75 (0.36-1.01) | 0.71 (0.36-0.9) | 0.76 (0.38-1.01) | .23 |
Abbreviations: EP: Etoposide + platinum, N = number.
aCumulative dose intensity: calculated as the cumulative actual dose divided by (standard dose × total cycles administered). The standard doses are cisplatin 75 mg/m² or carboplatin 5 AUC in day1 and etoposide 100 mg/m² on day 1 to day 3.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
